High debt and stretched receivables
Consolidated debt stands at ~₹960 crore, with receivables growing 45% YoY due to longer credit periods in emerging markets, straining cash flow.
INDOCOREMEDIES / Q4-FY26 / risks
Keep the risk register visible.
Indoco Remedies · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Unresolved sterile plant issue
The sterile plant at Pataganda remains unresolved, limiting future US approvals and requiring ongoing investment without immediate returns.
Exchange rate volatility on ECB loan
A €10 million ECB loan caused a ₹24 crore exchange loss in Q4, impacting finance costs; further currency fluctuations could hurt profitability.
Domestic business seasonality risk
Domestic formulation revenue declined 6% YoY due to weak seasonal demand for anti-infectives and respiratory products, with recovery uncertain.